TG Therapeutics Inc
tgtherapeutics.comTG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical company focused on the development and commercialization of treatments for B-cell diseases and other serious conditions. The company generates revenue through product sales of its approved therapies, supported by third-party manufacturing, distribution, and commercialization arrangements. The 10-K filed 2026-02-27 covers the fiscal year ended December 31, 2025. The filing indicates TGTX is listed on the Nasdaq Capital Market. The company relies on contractual relationships with third parties for manufacturing, distribution, and supply chain functions. Intellectual property protection covering its products and product candidates is cited as a key business consideration. The filing references ongoing commercialization efforts and revenue generation from approved drug products, with financial performance and cash burn management identified as material operational focus areas.
Products & Services
The filing references approved drug products and pipeline drug candidates focused on B-cell diseases and related serious conditions. Specific product names are not disclosed in the available filing excerpts.
Revenue Model
Product sales of approved pharmaceutical therapies, supported by third-party manufacturing and distribution arrangements. The filing references revenue projections and commercialization efforts but does not provide specific revenue figures in the available excerpts.
Customers & Markets
The filing references commercialization of drug products but does not specify customer segments, end markets, or customer concentration data in the available excerpts.
Geographic Exposure
The filing does not provide geographic revenue breakdown or specific market footprint data in the available excerpts.
Loading...
